CraniUS Therapeutics secures rapid FDA 510(k) clearance and a U.S. patent for its NeuroPASS cranial drug‑delivery system
Executive summary: CraniUS Therapeutics obtained a second FDA 510(k) clearance for its NeuroPASS 2 plate configuration and received a U.S. patent for the NeuroPASS 3 cranial drug‑delivery system. The combined clearance and patent accelerate potential commercialization, lower regulatory hurdles, and protect the core technology from competitors.
Who is involved: CraniUS Therapeutics, the U.S. Food and Drug Administration (FDA), and the United States Patent and Trademark Office (USPTO).
Likely next (inference): The company is expected to pursue manufacturing scale‑up and launch preparations for the NeuroPASS platform in the United States.
On October 7, 2026, CraniUS Therapeutics announced that it received a second FDA 510(k) clearance within six weeks for a new plate configuration of its NeuroPASS system, which adds an opening for an implantable intracranial pressure sensor. Simultaneously, the company was granted a U.S. patent covering the integrated drug‑delivery architecture at the core of NeuroPASS 3. These back‑to‑back regulatory and intellectual‑property milestones reduce time‑to‑market risk and strengthen the company’s defensive position in the neurotechnology space.
Timeline
- — CraniUS Therapeutics Secures Second FDA 510(k) Clearance in Six Weeks and Earns U.S. Patent for NeuroPASS™ 3 Cranial Drug Delivery System (PR Newswire)
Analysis — what this means
Sectors affected
- Neurotechnology
- Cranial drug delivery
- Medical devices
Regulatory implications
- FDA 510(k) clearance permits U.S. market entry for the NeuroPASS platform
- U.S. patent protects the integrated drug‑delivery architecture, providing exclusive rights
Key entities
Sources
Related cases
- Sonorous Neurovascular secures FDA IDE approval to launch first U.S. pivotal trial of a venous sinus stent for pulsatile tinnitus
- FDA’s expanded allowance for non‑animal safety testing enables VivoSim’s human‑relevant models to cut drug‑development costs
- Dr. Oregonin secures FDA registration for OLTIS DENTAL‑X, launching a botanical oral‑care product grounded in a 1974 OSU discovery and two decades of South Korean research
- Roche’s BTK inhibitor fenebrutinib gains FDA filing acceptance for both relapsing and primary progressive MS, marking a potential first-in-class oral therapy
- Food safety attorney pushes FDA for mandatory warning labels on raw sprouts following multi-state outbreak
- XtalPi files first IND for AI-discovered gut-restricted pan-TRK inhibitor, marking clinical-stage transition